29/05/2022
Better late than never.
This is a topical game changer without any atrophy, stria, or telangiectasias of steroids.
Approval was based on results of three studies in a phase 3 clinical trial program, PSOARING, 1, 2, and an open-label extension study, PSOARING 3.